{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:07:03Z","timestamp":1787497623349,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofilament light chain (NfL) is an axonal cytoskeletal protein that is released into the extracellular space following neuronal or axonal injury associated with neurological conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and other diseases. NfL is detectable in the cerebrospinal fluid (CSF) and blood. Numerous studies on MS have demonstrated that NfL is correlated with disease activity, predicts disease progression, and is reduced by treatment with MS disease-modifying drugs, making NfL an attractive candidate to supplement existing clinical and imaging measures in MS. However, for NfL to achieve its potential as a clinically useful biomarker for clinical decision-making or drug development, a standardized, practical, and widely accessible assay is needed. Our objective was to develop a novel NfL assay on an automated, globally available immunoassay platform and validate its performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prototype NfL assay was first developed and evaluated on the ADVIA Centaur\n                      <jats:sup>\u00ae<\/jats:sup>\n                      XP immunoassay system from Siemens Healthineers. The lower limit of quantitation (LLoQ), within-lab precision, assay range, cross-reactivity with neurofilament medium and heavy chains, and effect of interfering substances were determined. NfL assay values in serum and CSF were compared with radiological and clinical disease activity measures in patients with MS and ALS, respectively. This assay was further optimized to utilize serum, plasma, and CSF sample types on the Atellica\n                      <jats:sup>\u00ae<\/jats:sup>\n                      IM system and transferred to Siemens' CLIA laboratory where it was analytically validated as a laboratory-developed test (LDT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this study, an LLoQ of 1.85 pg\/mL, within-lab precision &amp;lt;6%, and an assay range of up to 646 pg\/mL were demonstrated with the serum prototype assay. Cross-reactivity of &amp;lt;0.7% with the neurofilament medium and heavy chains was observed. Serum and CSF NfL assay values were associated with radiological and clinical disease activity measures in patients with MS and ALS, respectively. The optimized version of the NfL assay demonstrated specimen equivalence with additional plasma tube types and was analytically validated as an LDT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The analytical performance of the NfL assay fulfilled all acceptance criteria; therefore, we suggest that the assay is acceptable for use in both research and clinical practice settings to determine elevated NfL levels in patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2022.935382","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T11:31:15Z","timestamp":1658748675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform"],"prefix":"10.3389","volume":"13","author":[{"given":"Stephen","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Plavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangnan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Rudick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denitza","family":"Raitcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Matias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arejas J.","family":"Uzgiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrneurol.2015.173","article-title":"Body fluid biomarkers for multiple sclerosis\u2013the long road to clinical application","volume":"11","author":"Teunissen","year":"2015","journal-title":"Nat Rev Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/978-3-319-57193-5_20","article-title":"Biomarkers in neurodegenerative diseases","volume":"15","author":"Jeromin","year":"2017","journal-title":"Adv Neurobiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.tips.2020.09.011","article-title":"CSF and Blood biomarkers in neuroinflammatory and neurodegenerative diseases: implications for treatment","volume":"41","author":"Gaetani","year":"2020","journal-title":"Trends Pharmacol Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9334","DOI":"10.1074\/jbc.270.16.9334","article-title":"Neurofilament protein heterotetramers as assembly intermediates","volume":"270","author":"Cohlberg","year":"1995","journal-title":"J Biol Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/1352458512443092","article-title":"Neurofilaments as biomarkers in multiple sclerosis","volume":"18","author":"Teunissen","year":"2012","journal-title":"Mult Scler."},{"key":"B7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ncb0804-699","article-title":"Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds","volume":"6","author":"Coulombe","year":"2004","journal-title":"Nat Cell Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1007\/s12035-020-02035-9","article-title":"Different clinical contexts of use of blood neurofilament light chain protein in the spectrum of neurodegenerative diseases","volume":"57","author":"Palermo","year":"2020","journal-title":"Mol Neurobiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2016278","DOI":"10.1001\/jamanetworkopen.2020.16278","article-title":"Association of serum neurofilament light levels with long-term brain atrophy in patients with a first multiple sclerosis episode","volume":"3","author":"Plavina","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1177\/1352458520972573","article-title":"Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring","volume":"27","author":"Calabresi","year":"2021","journal-title":"Mult Scler."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","article-title":"Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis","volume":"10","author":"Thebault","year":"2020","journal-title":"Sci Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2019-321321","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1212\/WNL.0000000000009097","article-title":"Blood neurofilament light levels segregate treatment effects in multiple sclerosis","volume":"94","author":"Delcoigne","year":"2020","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3389\/fneur.2020.00919","article-title":"CSF neurofilament light chain elevation predicts ALS severity and progression","volume":"11","author":"Sun","year":"2020","journal-title":"Front Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.4155\/bio-2019-0163","article-title":"Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood","volume":"11","author":"Hendricks","year":"2019","journal-title":"Bioanalysis."},{"key":"B18","article-title":"Supplemental Tables for Interference Testing in Clinical Chemistry-First Edition","year":"2018"},{"key":"B19","article-title":"Evaluation of precision of quantitative measurement procedures; Approved Guideline\u2014Third Edition","year":"2014"},{"key":"B20","article-title":"Evaluation of detection capability for clinical laboratory measurement procedures; Approved Guideline-Second Edition","year":"2012"},{"key":"B21","volume-title":"Evaluation of the Linearity of Quantitative Measurement Procedures; Approved Guideline","year":"2003"},{"key":"B22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fneur.2020.00632","article-title":"Harnessing real-world data to inform decision-making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)","volume":"11","author":"Mowry","year":"2020","journal-title":"Front Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","article-title":"Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF","volume":"67","author":"Rosengren","year":"1996","journal-title":"J Neurochem."},{"key":"B25","unstructured":"Hemoglobin Test (2022)\n            ClinicM"},{"key":"B26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal associations of Blood Phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/ane.12151","article-title":"Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis","volume":"128","author":"Kuhle","year":"2013","journal-title":"Acta Neurol Scand."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/cells10061537","article-title":"Neurofilament Light Chain (NfL) in Blood-A biomarker predicting unfavourable outcome in the acute phase and improvement in the late phase after stroke","volume":"10","author":"Pekny","year":"2021","journal-title":"Cells."},{"key":"B29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann Clin Transl Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.935382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T11:31:19Z","timestamp":1658748679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.935382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":30,"alternative-id":["10.3389\/fneur.2022.935382"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.935382","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.17.22273097","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"article-number":"935382"}}